Search Result
Results for "
antiplatelet
" in MedChemExpress (MCE) Product Catalog:
3
Biochemical Assay Reagents
4
Isotope-Labeled Compounds
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-15876
-
-
-
- HY-78542
-
-
-
- HY-N2299
-
|
|
Others
|
Cardiovascular Disease
|
|
Morusinol is a flavonoid isolated from Morus alba root bark. Morusinol has an antiplatelet activity and significantly inhibits arterial thrombosis in vivo .
|
-
-
- HY-146499
-
|
|
P2Y Receptor
|
Cardiovascular Disease
Cancer
|
|
Antiplatelet agent 2 (compound 7p) is a Ticagrelor analoguehas, possessing antiplatelet activity. Antiplatelet agent 2 can be used for researching platelet aggregation .
|
-
-
- HY-146498
-
|
|
P2Y Receptor
|
Cardiovascular Disease
Cancer
|
|
Antiplatelet agent 1 (compound 7q) is a Ticagrelor analoguehas, possessing antiplatelet activity. Antiplatelet agent 1 can be used for researching platelet aggregation .
|
-
-
- HY-111755
-
|
|
P2Y Receptor
|
Cardiovascular Disease
|
|
Oral antiplatelet agent 1 is a potent P2Y12 receptor antagonist. Oral antiplatelet agent 1 exhibits excellent antiplatelet aggregation potency with an IC50 value of 2.94 μM as well as antithrombotic efficacy in a rat ferric chloride model. Oral antiplatelet agent 1 shows a superior safety profile than Clopidogrel (HY-15283) in a rat tail-bleeding model. Oral antiplatelet agent 1 can be used to research thromboembolic disorders .
|
-
-
- HY-N7991
-
-
-
- HY-N1861
-
|
Quercetin 3-O-methyl ether peracetate
|
P2Y Receptor
|
Cardiovascular Disease
Cancer
|
|
3-O-Methylquercetin tetraacetate is an antiplatelet agent. 3-O-Methylquercetin tetraacetate has potent antiplatelet effect on arachidonic acid, collagen-induced and PAF-induced platelet aggregation .
|
-
-
- HY-N3048
-
|
|
Others
|
Cardiovascular Disease
|
|
Piperlotine D is an antiplatelet aggregation agent. Piperlotine D can be extracted from Piper lolot with antiplatelet aggregation activity. Piperlotine D inhibits arachidonic acid-induced platelet aggregation with an IC50 of 43.4 μg/mL .
|
-
-
- HY-162374
-
|
|
Calcium Channel
|
Cardiovascular Disease
|
|
ANO61 is a dibenzyl formamide derivative, which exhibits an antiplatelet efficacy through modulation of thrombin-induced Ca 2+ response with an IC50 of 47.7 μM .
|
-
-
- HY-N2909
-
|
|
Others
|
Inflammation/Immunology
Cancer
|
|
Aurantiamide is an orally active constituent of Portulaca oleracea L and has various biological activities, including antioxidant, antiplatelet, anti-inflammatory, and antitumor activities .
|
-
-
- HY-118072
-
-
-
- HY-110118
-
|
|
PPAR
|
Metabolic Disease
|
|
Edaglitazone is a potent, selective and orally active PPARγ agonist, with EC50s of 35.6 nM and 1053 nM for PPARα and PPARγ, respectively. Edaglitazone displays antiplatelet, antidiabetic and anti-hyperglycemic activity .
|
-
-
- HY-125123
-
|
|
Integrin
|
Cardiovascular Disease
|
|
Euchrestaflavanone A is a flavonoid found in the root bark of Cudrania tricuspidate. Euchrestaflavanone A inhibits platelet aggregation and has some antiplatelet and antithrombotic properties, making it a potential compound for thromboprophylaxis .
|
-
-
- HY-119410
-
|
HN11500
|
Prostaglandin Receptor
|
Cardiovascular Disease
|
|
Linotroban (HN11500), a Sulotroban (HY-158332) derivative, is an orally active, potent non-prostanoid thromboxane receptor antagonist (TXRA) with a strong antiplatelet profile. Linotroban is used as antithrombotic agent .
|
-
-
- HY-B1735
-
|
|
Prostaglandin Receptor
|
Cardiovascular Disease
|
|
Picotamide is a combined inhibitor of thromboxane A2 (TxA2) synthase and receptor. Picotamide has antiplatelet activity. Picotamide promotes the reduction of microalbuminuria and the inhibition of growth of carotid plaques in diabetes. Picotamide can be used for researching acute or chronic cardiovascular diseases .
|
-
-
- HY-15799
-
|
|
P2Y Receptor
|
Cardiovascular Disease
|
|
AZD1283 is a potent P2Y12 receptor antagonist with a binding IC50 of 11 nM and a GTPγS IC50 of 25 nM. AZD1283 has excellent antiplatelet aggregation potency. AZD1283 can be used to research thromboembolic disorders .
|
-
-
- HY-B1622
-
-
-
- HY-B0366A
-
|
|
5-HT Receptor
|
Cardiovascular Disease
Neurological Disease
Cancer
|
|
Cyproheptadine hydrochloride is a potent and orally active 5-HT2A receptor antagonist, with antidepressant and antiserotonergic effects. Cyproheptadine hydrochloride has antiplatelet and thromboprotective activities. Cyproheptadine hydrochloride can be used for the research of thromboembolic disorders .
|
-
-
- HY-N15271
-
-
-
- HY-N2081
-
|
|
Others
|
Inflammation/Immunology
Cancer
|
|
Skimmianine is a furoquinoline alkaloid present mainly in the Rutaceae family, with antispastic, anti-inflammatory activities and antiplatelet aggregation effect. Skimmianine exhibits cytotoxicity against a variety of cancer cell lines and genotoxicity .
|
-
-
- HY-N6020A
-
|
|
Others
|
Others
|
|
(+)-Butin is the R enantiomer of Butin. Butin is a major biologically active flavonoid isolated from the heartwood of Dalbergia odorifera, with strong antioxidant, antiplatelet and anti-inflammatory activities .
|
-
-
- HY-B0428B
-
|
OKY-046 hydrochloride
|
Prostaglandin Receptor
|
Cardiovascular Disease
|
|
Ozagrel hydrochloride (OKY-046 hydrochloride) is a thromboxane A2 (TXA2) synthase inhibitor. Ozagrel hydrochloride is an antiplatelet agent, which selectively inhibits human platelet aggregationwith an IC50 of 53.12 μM .
|
-
-
- HY-B0428A
-
|
OKY-046 sodium
|
Prostaglandin Receptor
|
Cardiovascular Disease
|
|
Ozagrel sodium (OKY-046 sodium) is a thromboxane A2 (TXA2) synthase inhibitor. Ozagrel sodium is an antiplatelet agent, which selectively inhibits human platelet aggregation with an IC50 of 53.12 μM .
|
-
-
- HY-B0312
-
-
-
- HY-162409
-
|
|
Protease Activated Receptor (PAR)
|
Others
|
|
PAR4 antagonist 4 (Compound 37) is a selective antagonist for protease activated receptor 4 (PAR4). PAR4 antagonist 3 exhibits antiplatelet efficacy with IC50 of 14.2 nM. PAR4 antagonist 3 improves metabolic stablility in human liver microsomes with T1/2 of 42.5 min .
|
-
-
- HY-162408
-
|
|
Protease Activated Receptor (PAR)
|
Others
|
|
PAR4 antagonist 3 (Compound 36) is a selective antagonist for protease activated receptor 4 (PAR4). PAR4 antagonist 3 exhibits antiplatelet efficacy with IC50 of 26.1 nM. PAR4 antagonist 3 improves metabolic stablility in human liver microsomes with T1/2 of 97.6 min .
|
-
-
- HY-B0428
-
Ozagrel
1 Publications Verification
OKY-046
|
Prostaglandin Receptor
|
Cardiovascular Disease
|
|
Ozagrel (OKY-046)is an anti-asthmatic agent and a thromboxane A2 (TXA2) synthase inhibitor. Ozagrel is an antiplatelet agent, which selectively inhibits human platelet aggregation with an IC50 of 53.12 μM .
|
-
-
- HY-106066
-
|
UK38485
|
Prostaglandin Receptor
|
Cardiovascular Disease
|
|
Dazmegrel (UK-38485) is a thromboxane synthetase inhibitor which inhibits Thromboxane A2 (TXA2) synthesis and exhibits antiplatelet vasodilator effects. Dazmegrel can be utilized in thrombosis research .
|
-
-
- HY-A0221
-
|
R 68070
|
Prostaglandin Receptor
|
Inflammation/Immunology
|
|
Ridogrel (R 68070) is an orally active combined thromboxane A2 synthetase inhibitor and thromboxane A2/prostaglandin endoperoxide receptor blocker. Ridogrel is potent antiplatelet agent. Anti-inflammatory activities .
|
-
-
- HY-B1622R
-
|
|
5-HT Receptor
Apoptosis
|
Cardiovascular Disease
Neurological Disease
|
|
Cyproheptadine (Standard) is the analytical standard of Cyproheptadine. This product is intended for research and analytical applications. Cyproheptadine is a potent and orally active 5-HT2A receptor antagonist, with antidepressant and antiserotonergic effects. Cyproheptadine has antiplatelet and thromboprotective activities. Cyproheptadine can be used for the research of thromboembolic disorders .
|
-
-
- HY-B0366AR
-
|
|
5-HT Receptor
|
Cardiovascular Disease
Neurological Disease
Cancer
|
|
Cyproheptadine (hydrochloride) (Standard) is the analytical standard of Cyproheptadine (hydrochloride). This product is intended for research and analytical applications. Cyproheptadine hydrochloride is a potent and orally active 5-HT2A receptor antagonist, with antidepressant and antiserotonergic effects. Cyproheptadine hydrochloride has antiplatelet and thromboprotective activities. Cyproheptadine hydrochloride can be used for the research of thromboembolic disorders .
|
-
-
- HY-N2081R
-
|
|
Others
|
Inflammation/Immunology
Cancer
|
|
Skimmianine (Standard) is the analytical standard of Skimmianine. This product is intended for research and analytical applications. Skimmianine is a furoquinoline alkaloid present mainly in the Rutaceae family, with antispastic, anti-inflammatory activities and antiplatelet aggregation effect. Skimmianine exhibits cytotoxicity against a variety of cancer cell lines and genotoxicity .
|
-
-
- HY-B0428BR
-
|
|
Prostaglandin Receptor
|
Cardiovascular Disease
|
|
Ozagrel (hydrochloride) (Standard) is the analytical standard of Ozagrel (hydrochloride). This product is intended for research and analytical applications. Ozagrel hydrochloride (OKY-046 hydrochloride) is a thromboxane A2 (TXA2) synthase inhibitor. Ozagrel hydrochloride is an antiplatelet agent, which selectively inhibits human platelet aggregationwith an IC50 of 53.12 μM .
|
-
-
- HY-B0312R
-
|
|
Phosphodiesterase (PDE)
Apoptosis
|
Cardiovascular Disease
Cancer
|
|
Dipyridamole (Standard) is the analytical standard of Dipyridamole. This product is intended for research and analytical applications. Dipyridamole is an orally active phosphodiesterase (PDE) inhibitor. Dipyridamole also is an antiplatelet agent used in secondary prophylaxis against stroke. Dipyridamole can induce cancer cell-specific apoptosis .
|
-
-
- HY-N1631
-
|
1-Hydroxyrutaecarpine
|
Drug Derivative
|
Others
|
|
1-Hydroxyrutaecarpine (compound 1a) is a hydroxy-derivative of rutaecarpine. 1-Hydroxyrutaecarpine shows cytotoxicities with ED50s of 3.72, 7.44 µg/mL for P-388 and HT-29 cells, respectively. 1-Hydroxyrutaecarpine shows antiplatelet activity .
|
-
-
- HY-N11920
-
-
-
- HY-N9488
-
|
Girinimbin
|
Apoptosis
Bacterial
Parasite
|
Infection
Inflammation/Immunology
Cancer
|
|
Girinimbine (Girinimbin) is a carbazole alkaloid with a variety of biological effects. Girinimbine can induce apoptosis, and has antitrypanosomal, antiplatelet activity, antibacterial activity, anti-inflammatory, antioxidant and antitumor activities .
|
-
-
- HY-19638A
-
|
AR-C69931MX tetrasodium
|
P2Y Receptor
|
Cardiovascular Disease
Inflammation/Immunology
|
|
Cangrelor tetrasodium, an adenosine triphosphate analogue, is a reversible and selective platelet P2Y12 antagonist, with prompt and potent antiplatelet effects. Cangrelor tetrasodium directly blocks adenosine diphosphate (ADP)-induced activation and aggregation of platelets. Cangrelor tetrasodium is also a nonspecific GPR17 antagonist .
|
-
-
- HY-P99560
-
|
C4G1; YM-337
|
Integrin
|
Cardiovascular Disease
|
|
Tadocizumab (C4G1; YM-337) is a humanized monoclonal antibody tageting integrin αIIbβ3. Tadocizumab has antiplatelet and antithrombotic effects, and can be used for cardiovascular disease research .
|
-
-
- HY-106080A
-
|
U-63557A
|
Prostaglandin Receptor
|
Cardiovascular Disease
|
|
Furegrelate Sodium (U-63557A) is a potent, orally available, and selective thromboxane synthase inhibitor. Furegrelate Sodium inhibits human platelet microsomal thromboxane A2 (TxA2) synthase with an IC50 of 15 nM. Furegrelate Sodium is being developed as an antiplatelet agent .
|
-
-
- HY-106080
-
|
U-63557A free acid
|
Prostaglandin Receptor
|
Cardiovascular Disease
|
|
Furegrelate (U-63557A free acid) is a potent, orally available, and selective thromboxane synthase inhibitor. Furegrelate inhibits human platelet microsomal thromboxane A2 (TxA2) synthase with an IC50 of 15 nM. Furegrelate is being developed as an antiplatelet agent .
|
-
-
- HY-118284
-
|
|
P2Y Receptor
|
Cardiovascular Disease
|
|
Vicagrel is a potent, safe and orally active antiplatelet agent, which works by irreversibly inhibiting P2Y12 receptor. Vicagrel can be used for the research of blood clots in coronary artery disease, peripheral vascular disease, and cerebrovascular disease .
|
-
-
- HY-105218A
-
|
BMS-180291 sodium
|
Prostaglandin Receptor
|
Cardiovascular Disease
Endocrinology
Cancer
|
|
Ifetroban (BMS-180291) sodium is an orally active antagonist of thromboxane A2 (TXA2) or prostaglandin H2 (PGH2) receptor. Ifetroban sodium shows antiplatelet activity, and inhibits tumor cell migration without affecting cell proliferation. Ifetroban sodium can be used for myocardial ischemia, hypertension, stroke, thrombosis, cardiomyopathy research .
|
-
-
- HY-105218
-
|
BMS-180291
|
Prostaglandin Receptor
|
Cardiovascular Disease
Endocrinology
Cancer
|
|
Ifetroban (BMS-180291) is an orally active antagonist of thromboxane A2 (TXA2) or prostaglandin H2 (PGH2) receptor. Ifetroban shows antiplatelet activity, and inhibits tumor cell migration without affecting cell proliferation. Ifetroban can be used for myocardial ischemia, hypertension, stroke, thrombosis, cardiomyopathy research .
|
-
-
- HY-115912
-
|
|
Glycoprotein VI
|
Cardiovascular Disease
|
|
GPVI antagonist 3 (Compound 2) is a potential antagonist of Glycoprotein VI (GPVI). IC50 values of GPVI antagonist 3 are, respectively, 1.01 μM for collagen, 1.92 μM for CRP, 7.24 μM for convulxin and 51.74 μM for thrombin. Glycoprotein VI (GPVI) is a platelet major collagen receptor and a target for potent and safe antithrombotic research. GPVI antagonist 3 is a promising antiplatelet agent .
|
-
-
- HY-115911
-
|
|
Glycoprotein VI
|
Cardiovascular Disease
|
|
GPVI antagonist 2 (Compound 1) is a potential antagonist of Glycoprotein VI (GPVI). IC50 values of GPVI antagonist 2 are, respectively, 0.35 μM for collagen, 0.80 μM for CRP, 195.2 μM for convulxin and 81.38 μM for thrombin. Glycoprotein VI (GPVI) is a platelet major collagen receptor and a target for potent and safe antithrombotic research. GPVI antagonist 2 is a promising antiplatelet agent .
|
-
-
- HY-17459
-
|
(S)-(+)-Clopidogrel bisulfate; (S)-(+)-Clopidogrel hydrogen sulfate
|
Cytochrome P450
P2Y Receptor
|
Cardiovascular Disease
Cancer
|
|
Clopidogrel hydrogen sulfate is an antiplatelet agent to prevent blood clots. Clopidogrel hydrogen sulfate inhibits CYP2B6 and CYP2C19 with IC50s of 18.2 nM and 524 nM, respectively . Clopidogrel hydrogen sulfate is a potent antithrombotic agent that inhibits ADP-induced platelet aggregation ．Clopidogrel hydrogen sulfate also is an orally active P2Y(12) inhibitor .
|
-
-
- HY-W062836
-
|
|
Guanylate Cyclase
|
Cardiovascular Disease
|
|
BAY 41-8543 is an orally active, nitric oxide (NO)-independent stimulator of soluble guanylyl cyclase (sGC). BAY 41-8543 has vasodilator activity in the pulmonary and systemic vascular beds in the rat. BAY 41-8543 has antiplatelet effects and has the potential for cardiovascular diseases research .
|
-
-
- HY-107146
-
|
P1pal-7
|
Protease Activated Receptor (PAR)
|
Cardiovascular Disease
Cancer
|
|
PZ-128 (P1pal-7), a cell-penetrating lipopeptide pepducin, is a first-in-class, specific and reversible protease-activated receptor-1 (PAR1) antagonist. PZ-128 targets the cytoplasmic surface of PAR1 and interrupts signaling to internally-located G (PAR1-G) proteins. PZ-128 has antiplatelet, anti-metastatic, anti-angiogenic and anticancer effects .
|
-
- HY-112575
-
|
|
NO Synthase
|
Infection
Cardiovascular Disease
Inflammation/Immunology
|
|
Tiazotic acid is a metabolic agent that has immunomodulatory, anti-inflammatory, antioxidant, anti-ischemic, cardio- and endothelioprotective, antiplatelet, hepatoprotective activities. Tiazotic acid increases the levels of eNOS. Tiazotic acid also reduces the level of D-dimer in the blood, which reduces the risks of heart attacks and strokes in post-COVID syndrome .
|
-
- HY-N0293
-
Paeoniflorin
Maximum Cited Publications
22 Publications Verification
Peoniflorin
|
HSP
|
Infection
Neurological Disease
Cancer
|
|
Paeoniflorin is a heat shock protein-inducing compound and commonly exists in the plants of Paeoniaceae family, with various biological activities, including anticancer activity, anti-inflammatory activity, enhancing cognition and attenuating learning impairment, anti-oxidative stress, antiplatelet aggregation, expansion of blood vessels, and reducing blood viscosity .
|
-
- HY-14937
-
-
- HY-119145
-
|
|
P2Y Receptor
|
Cardiovascular Disease
|
|
MRS2496 is a selective P2Y1 receptor antagonist with an IC50 value of 1.5 μM, exhibiting antiplatelet aggregation activity. MRS2496 can be used in the research of antiplatelet aggregation and blood-related diseases .
|
-
- HY-N3729
-
|
Denudatin B
|
Calcium Channel
|
Cardiovascular Disease
|
|
(-)-Denudatin B is an antiplatelet agent. (-)-Denudatin B relaxed vascular smooth muscle by inhibiting the Ca2+ influx through voltage-gated and receptor-operated Ca2+ channels . And (-)-Denudatin B has nonspecific antiplatelet action
|
-
- HY-N1723
-
-
- HY-N0293R
-
|
|
HSP
|
Infection
Neurological Disease
Cancer
|
|
Paeoniflorin (Standard) is the analytical standard of Paeoniflorin. This product is intended for research and analytical applications. Paeoniflorin is a heat shock protein-inducing compound and commonly exists in the plants of Paeoniaceae family, with various biological activities, including anticancer activity, anti-inflammatory activity, enhancing cognition and attenuating learning impairment, anti-oxidative stress, antiplatelet aggregation, expansion of blood vessels, and reducing blood viscosity .
|
-
- HY-B1016
-
-
- HY-19163
-
-
- HY-N3051
-
-
- HY-33351
-
-
- HY-125323
-
-
- HY-118025
-
|
(±)-SR-121683
|
Drug Metabolite
|
Others
|
|
(±)-2-Oxo clopidogrel is a metabolite of the antiplatelet agent Clopidogrel (HY-15283) .
|
-
- HY-N0320
-
-
- HY-N3047
-
|
O-Methylpiperolactam B; Piperolactam B methyl ether
|
Others
|
Cardiovascular Disease
|
|
Piperolactam C (O-Methylpiperolactam B) is a natural alkaloid with anti-platelet aggregation effects .
|
-
- HY-N1505
-
|
|
Akt
|
Cardiovascular Disease
|
|
Loureirin A is a flavonoid extracted from Dragon's Blood, can inhibit Akt phosphorylation, and has antiplatelet activity.
|
-
- HY-101700
-
-
- HY-U00039
-
-
- HY-121690
-
-
- HY-N3668
-
|
Cyclomorusin A; Cyclomulberrochromene
|
Others
|
Cardiovascular Disease
|
|
Cyclomorusin (Cyclomorusin A; Cyclomulberrochromene) is a prenylflavonoid with antiplatelet activity. Cyclomorusin also inhibits markedly collagen-induced platelet aggregation .
|
-
- HY-110265
-
-
- HY-B0686B
-
|
|
Integrin
|
Cardiovascular Disease
|
|
Eptifibatide acetate is a cyclic heptapeptide, acts as a competitive antagonist for the activated platelet glycoprotein IIb/IIIa receptor, with anti-platelet activity .
|
-
- HY-B0686
-
|
|
Integrin
|
Cardiovascular Disease
|
|
Eptifibatide is a cyclic heptapeptide, acts as a competitive antagonist for the activated platelet glycoprotein IIb/IIIa receptor, with anti-platelet activity .
|
-
- HY-124365
-
|
|
Others
|
Infection
Cancer
|
|
Rhamnetin tetraacetate (compound 4) is a xanthone compound with antiplatelet activity. Rhamnetin tetraacetate inhibited platelet aggregation induced by arachidonic acid .
|
-
- HY-171241
-
|
|
Drug Derivative
|
Cardiovascular Disease
|
|
Imolamine is a potent antiplatelet aggregation agent, is a phenyl aminoxidiazole derivative. Imolamine has the potential for the research of coronary heart disease .
|
-
- HY-B0686A
-
|
|
Integrin
|
Cardiovascular Disease
|
|
Eptifibatide monoacetate is a cyclic heptapeptide, acts as a competitive antagonist for the activated platelet glycoprotein IIb/IIIa receptor, with anti-platelet activity .
|
-
- HY-N3049
-
|
|
Others
|
Cardiovascular Disease
|
|
Piperlotine C is an alkaloid isolated from Piper lolot, with anti-platelet aggregation induced by arachidonic acid, and the IC50 is 26.6 µg/mL .
|
-
- HY-172181
-
|
|
P2Y Receptor
|
Cardiovascular Disease
|
|
NSC380324 is a P2Y12 receptor antagonist, possessing antiplatelet activity, and can be utilized in research on atherosclerotic cardiovascular diseases .
|
-
- HY-14851
-
|
Sonedenoson
|
Adenosine Receptor
|
Inflammation/Immunology
|
|
MRE 0094 (Sonedenoson) is a selective activator for adenosine receptor A2A, with a Ki of 490 nM. MRE 0094 exhibits anti-platelet and anti-inflammatory activities .
|
-
- HY-B0647A
-
-
- HY-B1016R
-
|
|
PDGFR
|
Cardiovascular Disease
Cancer
|
|
Trapidil (Standard) is the analytical standard of Trapidil. This product is intended for research and analytical applications. Trapidil is a vasodilator, an antiplatelet active molecule with specificity for platelet-derived growth factor.
|
-
- HY-N6020
-
|
|
Others
|
Inflammation/Immunology
|
|
(-)-Butin is the S enantiomer of Butin. Butin is a major biologically active flavonoid isolated from the heartwood of Dalbergia odorifera, with strong antioxidant, antiplatelet and anti-inflammatory activities .
|
-
- HY-123112
-
|
S792892A
|
Prostaglandin Receptor
|
Cardiovascular Disease
|
|
Hoe 892 (S792892A) is an orally active prostacyclin derivative with antiplatelet aggregation and vasodilatory activity. Hoe 892 can be used in the study of cardiovascular diseases such as thrombosis .
|
-
- HY-17487
-
|
Y 0213; Y 9213
|
COX
|
Neurological Disease
Inflammation/Immunology
|
|
Miroprofen (Y 0213) is an orally active nonsteroidal anti-inflammatory analgesic (NSAID). Miroprofen exhibits anti-inflammatory, analgesic and anti-platelet activities .
|
-
- HY-103386
-
|
|
COX
|
Inflammation/Immunology
|
|
FR122047 (hydrochloride) is a selective and oral active inhibitor of COX-1 with an IC50 of 28 nM. FR122047 hydrochloride has antiplatelet, analgesic and anti-inflammatory effects in vivo .
|
-
- HY-N1505R
-
|
|
Akt
|
Cardiovascular Disease
|
|
Loureirin A (Standard) is the analytical standard of Loureirin A. This product is intended for research and analytical applications. Loureirin A is a flavonoid extracted from Dragon's Blood, can inhibit Akt phosphorylation, and has antiplatelet activity.
|
-
- HY-N12647
-
|
|
Others
|
Infection
Inflammation/Immunology
|
|
cis-Hinkiresinol is a bioactive constituent of Rhizoma anemarrhenae. Rhizoma anemarrhenae is reprted to have anti-pathogenic microorganism, hypoglycemic effects, anti-inflammatory, antipyretic effects and anti-platelet aggregation .
|
-
- HY-N6806
-
-
- HY-162375
-
|
|
Drug Intermediate
|
Cardiovascular Disease
|
|
AF299 can reduce collagen-related peptide-induced platelet Ca 2+ rises and collagen-induced platelet aggregation. AF299 can be used for research of antiplatelet research .
|
-
- HY-169788
-
|
|
Others
|
Cardiovascular Disease
|
|
Graveolinine is a quinoline alkaloid, that can be isolated from Ruta chalepensis. Graveolinine exhibits antiplatelet activity, that reduces Arachidonic Acid (HY-109590)- and Collagen-induced aggregation of washed rabbit platelets .
|
-
- HY-N0320R
-
|
|
Others
|
Cardiovascular Disease
|
|
Salvianolic acid D (Standard) is the analytical standard of Salvianolic acid D. This product is intended for research and analytical applications. Salvianolic acid D, isolated from Salvia miltiorrhiza, is a potential antiplatelet activity compound .
|
-
- HY-11021
-
|
PRT060128
|
P2Y Receptor
|
Cardiovascular Disease
|
|
Elinogrel (PRT060128) is a potent, direct acting, competitive, and reversible platelet P2Y12 antagonist (IC50=20 nM). It is orally and intravenously available and has potent antiplatelet effects .
|
-
- HY-B0686BR
-
|
|
Integrin
|
Cardiovascular Disease
|
|
Eptifibatide (acetate) (Standard) is the analytical standard of Eptifibatide (acetate). This product is intended for research and analytical applications. Eptifibatide acetate is a cyclic heptapeptide, acts as a competitive antagonist for the activated platelet glycoprotein IIb/IIIa receptor, with anti-platelet activity .
|
-
- HY-108881R
-
|
|
Antibiotic
Cytochrome P450
Bacterial
|
Infection
Inflammation/Immunology
|
|
Eptifibatide (acetate) (Standard) is the analytical standard of Eptifibatide (acetate). This product is intended for research and analytical applications. Eptifibatide acetate is a cyclic heptapeptide, acts as a competitive antagonist for the activated platelet glycoprotein IIb/IIIa receptor, with anti-platelet activity .
|
-
- HY-U00367
-
-
- HY-167848
-
|
XL-118
|
Others
|
Cardiovascular Disease
|
|
DMP-728 free base (XL-118) is a highly potent and selective GPIIb/IIIa antagonist with antiplatelet and antithrombotic activities. DMP-728 free base can inhibit ADP-induced human platelet aggregation in vitro, with an IC50 of 46 nmol/L, and can significantly reduce the interaction between fibrinogen and human platelets or Binding of purified human GPIIb/IIIa receptors. DMP-728 free base exhibits dose-dependent antiplatelet effects in anesthetized mongrel dogs, effectively inhibiting ADP-induced platelet aggregation and prolonging template bleeding time .
|
-
- HY-W777681
-
-
- HY-126562
-
-
- HY-162558
-
|
|
Factor Xa
|
Cardiovascular Disease
|
|
NCGC00351170 is an antiplatelet agent that disrupts the calcium and integrin-binding protein 1 (CIB1)-αIIbβ3 interaction. NCGC00351170 inhibits thrombin-induced human platelet aggregation .
|
-
- HY-118025R
-
|
|
Drug Metabolite
|
Others
|
|
(±)-2-Oxo clopidogrel (Standard) is the analytical standard of (±)-2-Oxo clopidogrel. This product is intended for research and analytical applications. (±)-2-Oxo clopidogrel is a metabolite of the antiplatelet agent Clopidogrel (HY-15283) .
|
-
- HY-163504
-
-
- HY-111447
-
|
|
NADPH Oxidase
Apoptosis
|
Cardiovascular Disease
Cancer
|
|
VAS 3947, a specific NADPH oxidase (NOX) inhibitor, exerts a potent antiplatelet effect. VAS3947 induces apoptosis independently of anti-NOX activity, via UPR activation, mainly due to aggregation and misfolding of proteins .
|
-
- HY-N8425
-
|
Montanic acid
|
Endogenous Metabolite
|
Metabolic Disease
|
|
Octacosanoic acid is a very long-chain saturated fatty acid. It is the major component of D-003, a mixture of very long-chain aliphatic acids purified from sugar cane wax that has antiplatelet and cholesterol-lowering activities in animal models .
|
-
- HY-120080
-
|
|
Integrin
|
Others
|
|
UR-2922 is a platelet GPIIb/IIIa antagonist with antiplatelet aggregation and cardiovascular disease inhibition activities. UR-2922 has high affinity for human platelet receptors and has good pharmacokinetic properties, and can be used to inhibit cardiovascular diseases.
|
-
- HY-N12067
-
|
|
Others
|
Inflammation/Immunology
|
|
Columbianetin β-D-glucopyranoside can be isolated from Angelicae pubescentis radix and has antiplatelet aggregation, anti-inflammatory and analgesic activities. Columbianetin β-D-glucopyranoside exerts significant protective effects against glutamate-induced toxicity .
|
-
- HY-18200
-
|
E5555; ER-172594-00
|
Protease Activated Receptor (PAR)
JAK
Apoptosis
|
Cardiovascular Disease
Cancer
|
|
Atopaxar (E5555) is a potent, orally active, selective and reversible thrombin receptor protease-activated receptor-1 (PAR-1) antagonist. Atopaxar, an antiplatelet agent, interferes with platelet signaling. Atopaxar can be used for the research of atherothrombotic disease .
|
-
- HY-N0607
-
|
Polysciasaponin P3; Chikusetsusaponin 5; Chikusetsusaponin V
|
Calcium Channel
Prostaglandin Receptor
|
Cardiovascular Disease
Endocrinology
|
|
Ginsenoside Ro (Polysciasaponin P3; Chikusetsusaponin 5; Chikusetsusaponin V) exhibits a Ca 2+-antagonistic antiplatelet effect with an IC50 of 155 ?μM. Ginsenoside Ro reduces the production of TXA2 more than it reduces the activities of COX-1 and TXAS.
|
-
- HY-125615
-
|
|
Glycoprotein VI
|
Cardiovascular Disease
Others
|
|
DMP 728 methanesulfonate is a platelet glycoprotein (GP) IIb/IIIa receptor antagonist. DMP 728 methanesulfonate shows dose-dependent antiplatelet and antithrombotic effects. DMP 728 methanesulfonate can be used in the study of effective antithrombotic agents in thromboembolic diseases of coronary and peripheral arteries .
|
-
- HY-141749AS
-
|
CLPM-d4; SR 26334-d4
|
Isotope-Labeled Compounds
|
Cardiovascular Disease
|
|
Clopidogrel carboxylic acid-d4 is a deuterated derivative of Clopidogrel carboxylic acid, which is an inactive metabolite of the antiplatelet agent Clopidogrel (HY-15283) in plasma. Clopidogrel carboxylic acid-d4 can be used to further explore the metabolic characteristics of Clopidogrel .
|
-
- HY-15876R
-
|
|
Drug Metabolite
P2Y Receptor
|
Cardiovascular Disease
|
|
Cyhalofop (Standard) is the analytical standard of Cyhalofop. This product is intended for research and analytical applications. Cyhalofop (Cyhalofop acid), the primary metabolite of Cyhalofop-butyl (HY-B0861) in susceptible grasses, is the herbicidally active metabolite. Cyhalofop-butyl is an aryloxyphenoxypropionate post-emergence herbicide widely used around the world in agriculture .
|
-
- HY-19837
-
|
|
Protease Activated Receptor (PAR)
|
Inflammation/Immunology
|
|
BMS-986120 is a first-in-class oral and reversible protease-activated receptor 4 (PAR4) antagonist, with IC50s of 9.5 nM and 2.1 nM in human and monkey blood, respectively. BMS-986120 has potent and selective antiplatelet effects .
|
-
- HY-W699533
-
|
Valeryl-4-hydroxyvalsartan; CGP 71580
|
Drug Metabolite
|
Cardiovascular Disease
|
|
4-Hydroxy valsartan is a metabolite of Valsartan (HY-18204). 4-Hydroxy valsartan regulates the expression of platelet surface receptors and inhibits conventional plasma or whole blood collagen induced platelet aggregation. 4-Hydroxy valsartan has antiplatelet activity .
|
-
- HY-N6020B
-
|
|
Others
|
Cardiovascular Disease
Inflammation/Immunology
|
|
Butin is a major biologically active flavonoid isolated from the heartwood of Dalbergia odorifera with oral activity, with strong antioxidant, antiplatelet and anti-inflammatory activities. Butin significantly alleviates myocardial infarction and improves heart function, together with prevents diabetes-induced cardiac oxidative damage in rat .
|
-
- HY-167743
-
|
|
Endogenous Metabolite
|
Cardiovascular Disease
|
|
Platelet aggregation-IN-2 is an anti-platelet aggregation agent with significant anticoagulant activity. Platelet aggregation-IN-2 can inhibit platelet aggregation reaction and reduce the risk of thrombosis. The application of Platelet aggregation-IN-2 can potentially be used for the prevention and suppression of cardiovascular diseases .
|
-
- HY-18200B
-
|
E5555 hydrobromide; ER 172594-06
|
Protease Activated Receptor (PAR)
JAK
Apoptosis
|
Cardiovascular Disease
Cancer
|
|
Atopaxar (E5555) hydrobromide is a potent, orally active, selective and reversible thrombin receptor protease-activated receptor-1 (PAR-1) antagonist. Atopaxar hydrobromide, an antiplatelet agent, interferes with platelet signaling. Atopaxar hydrobromide can be used for the research of atherothrombotic disease .
|
-
- HY-N3665
-
|
|
Tyrosinase
|
Cancer
|
|
Cyclocommunol is a prenylflavonoid with antityrosinase and antiplatelet activitie, can be solated from breadfruit. Cyclocommunol exerts anti-tumor activity and inhibits the growth of human hepatoma and gastric cancer cells with IC50 values between 16 and 80 µM. Cyclocommunol shows proapoptotic effect on oral squamous cell carcinoma (OSCC) .
|
-
- HY-N6005
-
|
|
Bacterial
|
Infection
Cancer
|
|
Methyl caffeate, an antimicrobial agent, shows moderate antimicrobial and prominent antimycobacterial activities. Methyl caffeate also exhibits α-glucosidase inhibition activity, oxidative stress inhibiting activity, anti-platelet activity, antiproliferative activity in cervix adenocarcinoma and anticancer activity in lung and leukmia cell lines .
|
-
- HY-NP026
-
|
C-phycocyaninfromporphyratenera
|
SOD
Integrin
|
Inflammation/Immunology
|
|
Spirulina C-phycocyanin, a component of the light-harvesting phycobilisome complex in photosystem II, is a highly dominant chromoprotein in Spirulina. Spirulina C-phycocyanin can be detected by Raman spectral measurement. Spirulina C-phycocyanin has antioxidant, anti-inflammatory, antiplatelet, liver-protective and cholesterol-lowering effects .
|
-
- HY-B0428D
-
|
(E/Z)-OKY-046 sodium
|
Prostaglandin Receptor
|
Cardiovascular Disease
|
|
(E/Z)-Ozagrel (sodium) [(E/Z)-OKY-046 (sodium)] is an EZ configuration mixture of Ozagrel (sodium) (HY-B0428A). Ozagrel (sodium) is a thromboxane A2 (TXA2) synthase inhibitor. Ozagrel (sodium) is an antiplatelet agent, which selectively inhibits human platelet aggregation with an IC50 of 53.12 μM .
|
-
- HY-10119
-
|
SCH 530348
|
Protease Activated Receptor (PAR)
|
Cardiovascular Disease
|
|
Vorapaxar (SCH 530348), an antiplatelet agent, is a selective, orally active, and competitive thrombin receptor protease-activated receptor (PAR-1) antagonist (Ki=8.1 nM). Vorapaxar (SCH 530348) inhibits thrombin receptor-activating peptide (TRAP)-induced platelet aggregation in a dose-dependent manner .
|
-
- HY-10119A
-
|
SCH 530348 sulfate
|
Protease Activated Receptor (PAR)
|
Cardiovascular Disease
|
|
Vorapaxar sulfate (SCH 530348 sulfate), an antiplatelet agent, is a selective, orally active, and competitive thrombin receptor protease-activated receptor (PAR-1) antagonist (Ki=8.1 nM). Vorapaxar sulfate inhibits thrombin receptor-activating peptide (TRAP)-induced platelet aggregation in a dose-dependent manner .
|
-
- HY-120636
-
|
|
P2Y Receptor
|
Cardiovascular Disease
|
|
P2Y1 antagonist 1 (compound 10q) is a potent antagonist of P2Y1, with the IC50s of 1.1 nM and 0.24 μM in FLIPR assay and hPA assay, respectively. P2Y1 antagonist 1 plays an important role in antiplatelet research .
|
-
- HY-123669A
-
|
|
P2Y Receptor
|
Cardiovascular Disease
|
|
Trans-R-138727 is the trans isomer of R-138727 (HY-123669). R-138727 is the active metabolite of the antiplatelet agent Prasugrel (HY-15284). R-138727 is an irreversible inhibitor for the platelet receptor P2Y12, and inhibits ADP-induced platelet activation and aggregation .
|
-
- HY-N8425R
-
|
|
Endogenous Metabolite
|
Metabolic Disease
|
|
Octacosanoic acid (Standard) is the analytical standard of Octacosanoic acid. This product is intended for research and analytical applications. Octacosanoic acid is a very long-chain saturated fatty acid. It is the major component of D-003, a mixture of very long-chain aliphatic acids purified from sugar cane wax that has antiplatelet and cholesterol-lowering activities in animal models .
|
-
- HY-19638
-
|
AR-C69931MX
|
P2Y Receptor
|
Cardiovascular Disease
Inflammation/Immunology
|
|
Cangrelor (AR-C69931MX), an adenosine triphosphate analogue, is an intravenous, reversible and selective platelet P2Y12 antagonist, with prompt and potent antiplatelet effects. Cangrelor directly blocks adenosine diphosphate (ADP)-induced activation and aggregation of platelets. Cangrelor is also a nonspecific GPR17 antagonist .
|
-
- HY-134650
-
|
|
Biochemical Assay Reagents
|
Others
|
|
(4E)-7-(4-Hydroxyphenyl)-1-phenylhept-4-en-3-one (Compound 8) is a diarylheptanoid containing two benzene rings. Diarylheptanoid is widely distributed in Alpinia, and exhibits cytotoxic, anti-inflammatory, antiplatelet, antioxidant, and antiproliferative activities .
|
-
- HY-108555
-
|
|
Protease Activated Receptor (PAR)
|
Cardiovascular Disease
|
|
FR171113 is a specific and non-peptide thrombin receptor antagonist. FR171113 exhibits the antithrombotic effects of a PAR1 antagonist. FR171113 inhibits thrombin-induced platelet aggregation with an IC50 of 0.29 μM. .
|
-
- HY-107867
-
|
|
P2Y Receptor
|
Cardiovascular Disease
Inflammation/Immunology
|
|
(±)-Clopidogrel bisulfate is a platelet P2Y12 receptor inhibitor and an adenosine diphosphate (ADP) receptor antagonist. (±)-Clopidogrel bisulfate inhibits the binding of ADP to its receptors on the membranes of platelet cells, and blocks ADP-mediated activation of the glycoprotein GPIIb/IIIa complex. (±)-Clopidogrel bisulfate reduces vascular inflammation and angiotensin II induced-abdominal aortic aneurysm progression. (±)-Clopidogrel bisulfate has anti-inflammatory effects .
|
-
- HY-15284
-
|
PCR 4099
|
P2Y Receptor
|
Cardiovascular Disease
|
|
Prasugrel (PCR 4099), a thienopyridine and proagent, inhibits platelet function. Prasugrel is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation .
|
-
- HY-15284B
-
|
PCR 4099 (Maleic acid)
|
P2Y Receptor
|
Cardiovascular Disease
|
|
Prasugrel (PCR 4099) Maleic acid is a thienopyridine and proagent, inhibits platelet function. Prasugrel Maleic acid is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation .
|
-
- HY-15284AR
-
|
|
P2Y Receptor
|
Cardiovascular Disease
|
|
Prasugrel (hydrochloride) (Standard) is the analytical standard of Prasugrel (hydrochloride). This product is intended for research and analytical applications. Prasugrel hydrochloride (PCR 4099 hydrochloride), a thienopyridine and proagent, inhibits platelet function. Prasugrel hydrochloride is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation .
|
-
- HY-15284A
-
|
PCR 4099 hydrochloride
|
P2Y Receptor
|
Cardiovascular Disease
|
|
Prasugrel hydrochloride (PCR 4099 hydrochloride), a thienopyridine and proagent, inhibits platelet function. Prasugrel hydrochloride is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation .
|
-
- HY-B0757
-
|
|
Reactive Oxygen Species
|
Cardiovascular Disease
Inflammation/Immunology
|
|
Vitamin E nicotinate is the derivative of Vitamin E. Vitamin E nicotinate exhibits antioxidant activity and prevents lipid peroxidation. Vitamin E nicotinate upregulates levels of CD4+ T cells and IL-2, exhibits immunomodulatory activity. Vitamin E nicotinate exhibits antiplatelet and antihypertensive activities, that can be used in atherosclerosis and thrombosis ressearch .
|
-
- HY-167091
-
|
(Rac)-TRK-100 free acid; (Rac)-ML 1229
|
Prostaglandin Receptor
|
Cardiovascular Disease
|
|
(Rac)-Beraprost ((Rac)-ML 1229) is an orally active prostacyclin analog that inhibits the release of Ca 2+ from intracellular storage sites by binding to prostacyclin membrane receptors (Prostaglandin Receptor), leading to relaxation of smooth muscle cells and vasodilation. Beraprost has vasodilatory, antiplatelet, and cytoprotective effects, making it promising for research in the field of cardiovascular diseases, such as thromboangiitis obliterans and atherosclerosis .
|
-
- HY-N0120
-
|
(E/Z)-Piceid
|
Others
|
Inflammation/Immunology
|
|
(E/Z)-Polydatin ((E/Z)-Piceid) is the E/Z mixture of Polydatin (HY-N0120A). Polydatin is a monocrystalline compound originally isolated from the root and rhizome of Polygonum cuspidatum. (E/Z)-Polydatin has anti-platelet aggregation, anti-oxidative action of low-density lipoprotein (LDL), cardioprotective activity, anti-inflammatory and immune-regulating functions .
|
-
- HY-N0607R
-
|
|
Calcium Channel
Prostaglandin Receptor
|
Cardiovascular Disease
Endocrinology
|
|
Ginsenoside Ro (Standard) is the analytical standard of Ginsenoside Ro. This product is intended for research and analytical applications. Ginsenoside Ro (Polysciasaponin P3; Chikusetsusaponin 5; Chikusetsusaponin V) exhibits a Ca2+-antagonistic antiplatelet effect with an IC50 of 155 μM. Ginsenoside Ro reduces the production of TXA2 more than it reduces the activities of COX-1 and TXAS.
|
-
- HY-141749B
-
|
CLPM hydrochloride; SR 26334 hydrochloride
|
Drug Metabolite
|
Cardiovascular Disease
|
|
Clopidogrel carboxylic acid (CLPM) hydrochloride is an inactive metabolite of the widely used antiplatelet medication clopidogrel, which serves as a reference standard for quantitative analysis of clopidogrel metabolism. Clopidogrel carboxylic acid hydrochloride has been shown to represent approximately 85% of circulating clopidogrel, hydrolyzed from the active form by esterases. Clopidogrel carboxylic acid hydrochloride plays a crucial role in assessing the pharmacokinetics and bioavailability of clopidogrel in various clinical and research settings.
|
-
- HY-128345
-
|
|
Protease Activated Receptor (PAR)
|
Cardiovascular Disease
|
|
UDM-001651 is a potent, selective, and orally bioavailable protease-activated receptor 4 (PAR4) antagonist (IC50=4 nM; Kd=1.4 nM). UDM-001651 shows antiplatelet potency (IC50=25 nM) in a γ-thrombin-induced platelet-rich plasma aggregation assay (γ-Thr PRP) .
|
-
- HY-139254
-
|
IDR3O; I3O
|
CDK
GSK-3
JNK
|
Neurological Disease
|
|
Indirubin-3′-oxime (IDR3O), a synthetic derivative of indirubin, is a potent inhibitor of cyclin-dependent kinases (CDKs) and glycogen synthase kinase 3β (GSK3β). Indirubin-3′-oxime directly inhibits the activity of all three isoforms of JNK (JNK1, JNK2, and JNK3), with IC50s of 0.8 μM, 1.4 μM, and 1.0 μM, respectively. Indirubin-3′-oxime can enhance height growth via activation of Wnt/β-catenin signaling in chondrocytes .
|
-
- HY-N3646
-
|
|
Others
|
Others
Neurological Disease
Inflammation/Immunology
Cancer
|
|
Cudratricusxanthone A is isolated from Cudrania tricuspidata, and has anti-inflammatory, hepatoprotective, and anti-proliferative activities. Cudratricusxanthone A inhibits osteoclast differentiation and function in RAW 264.7 cells and mouse bone marrow monocytes .
|
-
- HY-10119R
-
|
|
Protease Activated Receptor (PAR)
|
Cardiovascular Disease
|
|
Vorapaxar (Standard) is the analytical standard of Vorapaxar. This product is intended for research and analytical applications. Vorapaxar (SCH 530348), an antiplatelet agent, is a selective, orally active, and competitive thrombin receptor protease-activated receptor (PAR-1) antagonist (Ki=8.1 nM). Vorapaxar (SCH 530348) inhibits thrombin receptor-activating peptide (TRAP)-induced platelet aggregation in a dose-dependent manner .
|
-
- HY-10119S
-
|
SCH 530348-d5
|
Protease Activated Receptor (PAR)
Isotope-Labeled Compounds
|
Cardiovascular Disease
|
|
Vorapaxar-d5 is deuterated labeled Vorapaxar (HY-10119). Vorapaxar (SCH 530348), an antiplatelet agent, is a selective, orally active, and competitive thrombin receptor protease-activated receptor (PAR-1) antagonist (Ki=8.1 nM). Vorapaxar (SCH 530348) inhibits thrombin receptor-activating peptide (TRAP)-induced platelet aggregation in a dose-dependent manner .
|
-
- HY-N2375
-
|
|
Wnt
β-catenin
p38 MAPK
|
Metabolic Disease
|
|
L-Quebrachitol is a methoxy analog of inositol isolated from plants, which has free-radical scavenging, gastroprotection, anti-platelet aggregation and anti-diabetic activity. L-Quebrachitol promotes osteoblastogenesis by uppregulation of BMP-2, runt-related transcription factor-2 (Runx2), MAPK (ERK, JNK, p38α), and Wnt/β-catenin signaling pathway .
|
-
- HY-10119AR
-
|
|
Protease Activated Receptor (PAR)
|
Cardiovascular Disease
|
|
Vorapaxar (sulfate) (Standard) is the analytical standard of Vorapaxar (sulfate). This product is intended for research and analytical applications. Vorapaxar sulfate (SCH 530348 sulfate), an antiplatelet agent, is a selective, orally active, and competitive thrombin receptor protease-activated receptor (PAR-1) antagonist (Ki=8.1 nM). Vorapaxar sulfate inhibits thrombin receptor-activating peptide (TRAP)-induced platelet aggregation in a dose-dependent manner .
|
-
- HY-W017158R
-
|
|
Endogenous Metabolite
|
Metabolic Disease
|
|
Vorapaxar (sulfate) (Standard) is the analytical standard of Vorapaxar (sulfate). This product is intended for research and analytical applications. Vorapaxar sulfate (SCH 530348 sulfate), an antiplatelet agent, is a selective, orally active, and competitive thrombin receptor protease-activated receptor (PAR-1) antagonist (Ki=8.1 nM). Vorapaxar sulfate inhibits thrombin receptor-activating peptide (TRAP)-induced platelet aggregation in a dose-dependent manner .
|
-
- HY-Z7721
-
|
(Rac)-TRK-100; (Rac)-ML 1129 sodium
|
Prostaglandin Receptor
|
Cardiovascular Disease
|
|
(Rac)-Beraprost ((Rac)-ML 1129) sodium is a racemic isomer of Beraprost sodium (HY-13569A). Beraprost sodium is an orally active prostacyclin analog that inhibits the release of Ca 2+ from intracellular storage sites by binding to prostacyclin membrane receptors (Prostaglandin Receptor), leading to relaxation of smooth muscle cells and vasodilation. Beraprost sodium has vasodilatory, antiplatelet, and cytoprotective effects, making it promising for research in the field of cardiovascular diseases, such as thromboangiitis obliterans and atherosclerosis .
|
-
- HY-10309
-
|
RO 48-3657
|
Integrin
|
Cardiovascular Disease
|
|
Sibrafiban (RO 48-3657) is the orally active, nonpeptide, double-proagent of Ro 44-3888 and a selective glycoprotein IIb/IIIa receptor antagonist. Sibrafiban inhibits platelet aggregation .
|
-
- HY-159895
-
|
|
Protease Activated Receptor (PAR)
|
Cardiovascular Disease
|
|
PAR4 antagonist 7 (Compound 20f) is selective PAR4 antagonist (IC50: 1.72 nM). PAR4 antagonist 7 inhibits PAR4 agonist-induced platelet aggregation. PAR4 antagonist 7 has good metabolic stability. PAR4 antagonist 7 does not show a bleeding tendency in mice .
|
-
- HY-124371
-
|
|
Phosphodiesterase (PDE)
|
Cardiovascular Disease
|
|
Amentoflavone hexaacetate is a 3,5-cyclic nucleotide phosphodiesterase inhibitor with antiplatelet aggregation activity. Amentoflavone hexaacetate can inhibit the aggregation of eluted human platelets induced by ADP or collagen. Amentoflavone hexaacetate can also inhibit the cAMP phosphodiesterase activity in human platelets. Amentoflavone hexaacetate can significantly increase the cAMP level of platelets in the presence of prostaglandin E1. Amentoflavone hexaacetate has anti-angiogenic and anti-metastatic effects .
|
-
- HY-122211
-
|
|
Endogenous Metabolite
|
Cardiovascular Disease
|
|
MRS2802 is a P2Y14 receptor agonist with an EC50 value of 63 nM. MRS2802 can effectively activate the P2Y14 receptor and may play a role in regulating platelet function. The selectivity and activity of MRS2802 are conducive to in-depth research on the biological functions and pharmacological properties of P2Y receptors. The development of MRS2802 provides a potential inhibitory strategy for the search for new antiplatelet compounds .
|
-
- HY-120265
-
|
|
PI3K
|
Cardiovascular Disease
|
|
MIPS-9922 is a potent and selective PI3Kβ inhibitor with an IC50 of 63 nM. MIPS-9922 inhibits PI3Kβ with >30-fold higher potency than PI3Kδ. MIPS-9922 blocks PI3K mediated activation of platelet glycoprotein αIIbβ3 activation and platelet adhesion in vitro. MIPS-9922 shows anti-platelet and anti-thrombotic activities .
|
-
- HY-W419570
-
|
|
P2Y Receptor
|
Cardiovascular Disease
|
|
(Rac)-BX 048 is a BX 048 racemate. BX 048 is a P2Y12 receptor antagonist. BX 048 inhibits ADP-induced platelet aggregation in human, dog and rat whole blood. BX 048 also inhibits Arachidonic acid (HY-109590) induced platelet aggregation (IC50 of 15 μM) .
|
-
- HY-W012814
-
|
|
Endogenous Metabolite
Apoptosis
Reactive Oxygen Species
|
Cardiovascular Disease
Inflammation/Immunology
Cancer
|
|
4-Methylcatechol is an intermediate in the degradation of some alkylbenzenes and an orally active suicide inhibitor of catechol 2,3-dioxygenase (C23O). 4-Methylcatechol induces apoptosis in melanoma cells through oxidative stress, but some studies have also shown that 4-Methylcatechol is carcinogenic. In addition, 4-Methylcatechol has antiplatelet and blood pressure-lowering activities. 4-Methylcatechol can also inhibit protein oxidation in beef but does not disulfide formation .
|
-
- HY-17459R
-
|
(S)-(+)-Clopidogrel bisulfate (Standard); (S)-(+)-Clopidogrel hydrogen sulfate (Standard)
|
Cytochrome P450
P2Y Receptor
|
Cardiovascular Disease
Cancer
|
|
Clopidogrel (hydrogen sulfate) (Standard) is the analytical standard of Clopidogrel (hydrogen sulfate). This product is intended for research and analytical applications. Clopidogrel hydrogen sulfate is an antiplatelet agent to prevent blood clots. Clopidogrel hydrogen sulfate inhibits CYP2B6 and CYP2C19 with IC50s of 18.2 nM and 524 nM, respectively . Clopidogrel hydrogen sulfate is a potent antithrombotic agent that inhibits ADP-induced platelet aggregation ．Clopidogrel hydrogen sulfate also is an orally active P2Y(12) inhibitor .
|
-
- HY-123823
-
|
NCX 4016
|
COX
Apoptosis
|
Cancer
|
|
Nitroaspirin (NCX 4016) is a nitric oxide (NO) donor and a nitro-derivative of Aspirin, which combines with Nitroaspirin to inhibit cyclooxygenase. Nitroaspirin (NCX 4016) has antithrombotic and anti-platelet properties and acts as a direct and irreversible inhibitor of COX-1. Nitroaspirin (NCX 4016) causes significant induction of cell cycle arrest and apoptosis in Cisplatin-resistant human ovarian cancer cells via down-regulation of EGFR/PI3K/STAT3 signaling and modulation of Bcl-2 family proteins .
|
-
- HY-17459S
-
|
(S)-(+)-Clopidogrel bisulfate-d3; (S)-(+)-Clopidogrel-d3 hydrogen sulfate
|
P2Y Receptor
Cytochrome P450
|
Cardiovascular Disease
|
|
Clopidogrel-d3 (hydrogen sulfate) is the deuterium labeled Clopidogrel hydrogen sulfate[1]. Clopidogrel hydrogen sulfate is an antiplatelet agent to prevent blood clots. Clopidogrel hydrogen sulfate inhibits CYP2B6 and CYP2C19 with IC50s of 18.2 nM and 524 nM, respectively. Clopidogrel hydrogen sulfate is a potent antithrombotic agent that inhibits ADP-induced platelet aggregation．Clopidogrel hydrogen sulfate also is an orally active P2Y(12) inhibitor[2][3][4][5][6].
|
-
- HY-18200A
-
|
E5555 hydrochloride; ER-172594-00 hydrochloride
|
Protease Activated Receptor (PAR)
JAK
Apoptosis
|
Cardiovascular Disease
Cancer
|
|
Atopaxar hydrochloride (E5555 hydrochloride) is the hydrochloride salt form of Atopaxar (HY-18200). Atopaxar hydrochloride is an orally active, selective and reversible antagonist for thrombin receptor protease-activated receptor-1 (PAR-1). Atopaxar hydrochloride is the inhibitor for Janus kinase 1 (JAK1) and JAK2, which inhibits the JAK-STAT with EC50 of 5.90 μM in A549. Atopaxar hydrochloride inhibits the cell viability of A549 (IC50=7.02 μM), arrests the cell cycle at G1 phase and induces apoptosis. Atopaxar hydrochloride exhibits antiplatelet and antitumor activities. Atopaxar hydrochloride can be used for the research of atherothrombotic disease .
|
-
- HY-N2435
-
|
|
COX
Apoptosis
|
Cancer
|
|
[8]-Shogaol, a kind of stimulating compound in ginger, has antiplatelet (IC50=5 μM), anti-cancer and anti-inflammatory activity. [8]-Shogaol inhibited COX-2 (IC50=17.5 μM), which led to the decline of human leukemia cells. 8-Shogaol Selective direction TAK1 sum TAK1-TAB1 (IC50=5 μM), suppress IKK, Akt sum MAPK signal pathway, and reverse synovitis synovial sum Air dampness (RA) .
|
-
![[8]-Shogaol](//file.medchemexpress.eu/product_pic/hy-n2435.gif)
- HY-78263
-
|
NSC 170724; 5-(2-Nitrovinyl)benzodioxole
|
Src
Syk
NOD-like Receptor (NLR)
Integrin
|
Cancer
|
|
MNS (NSC 170724), the beta-nitrostyrene derivative, is an orally active tyrosine kinase inhibitor and a broad-spectrum antiplatelet agent. MNS inhibits Src, Syk, and FAK with IC50 of 27.3, 2.8, and 97.6 μM, respectively. MNS inhibits NLRP3 inflammasome and β1 integrin. MNS completely inhibits U46619, ADP-, arachidonic acid-, collagen-, and thrombin-induced platelet aggregation with IC50 values of 2.1, 4.1, 5.8, 7.0, and 12.7 μM, respectively. MNS is cytotoxic to a variety of cells .
|
-
- HY-P1956
-
|
HSA
|
NF-κB
NO Synthase
|
Cardiovascular Disease
Inflammation/Immunology
Cancer
|
|
Human serum albumin (HSA) is the most abundant protein in plasma and is a major determinant of plasma oncotic pressure. Human serum albumin exhibits antioxidant, anticoagulant, anti-inflammatory, anti-platelet aggregation activities as well as colloid osmotic action. Human serum albumin can block the inhibitory effect of GML on human T cells, providing protective function for T cells. Human serum albumin is also associated with cardiovascular diseases and can partially prevent the LPS (HY-D1056) induced oxidative stress, as well as the upregulation of NF-κB, NF-κB, and peroxynitrite (ONOO −) in the vascular wall, contributing to the reduction of blood pressure .
|
-
- HY-N2515
-
|
|
NF-κB
PI3K
JAK
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
Ginsenoside Rk1 is a unique component created by processing the ginseng plant (mainly Sung Ginseng, SG) at high temperatures .
Ginsenoside Rk1 has anti-inflammatory effect, suppresses the activation of Jak2/Stat3 signaling pathway and NF-κB .
Ginsenoside Rk1 has anti-tumor effect, antiplatelet aggregation activities, anti-insulin resistance, nephroprotective effect, antimicrobial effect, cognitive function enhancement, lipid accumulation reduction and prevents osteoporosis .
Ginsenoside Rk1 induces cell apoptosis by triggering intracellular reactive oxygen species (ROS) generation and blocking PI3K/Akt pathway .
|
-
- HY-160615
-
-
- HY-N2435R
-
|
|
COX
Apoptosis
|
Cancer
|
|
-Shogaol (Standard) is the analytical standard of -Shogaol. This product is intended for research and analytical applications. -Shogaol, a kind of stimulating compound in ginger, has antiplatelet (IC50=5 μM), anti-cancer and anti-inflammatory activity. -Shogaol inhibited COX-2 (IC50=17.5 μM), which led to the decline of human leukemia cells. 8-Shogaol Selective direction TAK1 sum TAK1-TAB1 (IC50=5 μM), suppress IKK, Akt sum MAPK signal pathway, and reverse synovitis synovial sum Air dampness (RA) .
|
-
![[8]-Shogaol (Standard)](//file.medchemexpress.eu/product_pic/hy-n2435r.gif)
- HY-113469B
-
|
|
STING
Endogenous Metabolite
|
Inflammation/Immunology
|
|
Cyclic GMP TBAOH is an endogenous second messenger that triggers interferon production in response to cytoplasmic DNA. Cyclic GMP TBAOH can activate the stimulator of interferon genes (STING), activating the signaling cascade that leads to the production of type I interferons and other immune mediators. Cyclic-GMP-AMP, a conjugate of cyclic GMP and AMP, can induce IRF3 phosphorylation and nuclear translocation, enhancing antiviral immune responses. Cyclic GMP TBAOH may also activate PDE to degrade cAMP, inhibit myocardial calcium current ICa, and regulate myocardial contractility. The derivative of Cyclic GMP TBAOH, 8-Br-cGMP, has antiplatelet activity, and Cyclic GMP TBAOH can be used in the study of antiviral immunity and cardiovascular diseases .
|
-
- HY-113469R
-
|
|
STING
Endogenous Metabolite
|
Inflammation/Immunology
|
|
Cyclic GMP (Standard) is the analytical standard of Cyclic GMP. This product is intended for research and analytical applications. Cyclic GMP is an endogenous second messenger that triggers interferon production in response to cytoplasmic DNA. Cyclic GMP can activate the stimulator of interferon genes (STING), activating the signaling cascade that leads to the production of type I interferons and other immune mediators. Cyclic-GMP-AMP, a conjugate of cyclic GMP and AMP, can induce IRF3 phosphorylation and nuclear translocation, enhancing antiviral immune responses. Cyclic GMP may also activate PDE to degrade cAMP, inhibit myocardial calcium current ICa, and regulate myocardial contractility. The derivative of Cyclic GMP, 8-Br-cGMP, has antiplatelet activity, and Cyclic GMP can be used in the study of antiviral immunity and cardiovascular diseases.
|
-
- HY-113469A
-
|
|
STING
Endogenous Metabolite
|
Inflammation/Immunology
|
|
Cyclic GMP (cGAMP) sodium is an endogenous second messenger that triggers interferon production in response to cytoplasmic DNA. Cyclic GMP sodium can activate the stimulator of interferon genes (STING), activating the signaling cascade that leads to the production of type I interferons and other immune mediators. Cyclic-GMP-AMP, a conjugate of cyclic GMP and AMP, can induce IRF3 phosphorylation and nuclear translocation, enhancing antiviral immune responses. Cyclic GMP sodium may also activate PDE to degrade cAMP, inhibit myocardial calcium current ICa, and regulate myocardial contractility. The derivative of Cyclic GMP sodium, 8-Br-cGMP, has antiplatelet activity, and Cyclic GMP sodium can be used in the study of antiviral immunity and cardiovascular diseases .
|
-
- HY-113469
-
|
|
STING
Endogenous Metabolite
|
Inflammation/Immunology
|
|
Cyclic GMP (cGAMP) is an endogenous second messenger that triggers interferon production in response to cytoplasmic DNA. Cyclic GMP can activate the stimulator of interferon genes (STING), activating the signaling cascade that leads to the production of type I interferons and other immune mediators. Cyclic-GMP-AMP, a conjugate of cyclic GMP and AMP, can induce IRF3 phosphorylation and nuclear translocation, enhancing antiviral immune responses. cGMP may also activate PDE to degrade cAMP, inhibit myocardial calcium current ICa, and regulate myocardial contractility. The derivative of cyclic GMP (cGMP), 8-Br-cGMP, has antiplatelet activity, and cyclic GMP can be used in the study of antiviral immunity and cardiovascular diseases .
|
-
- HY-149454
-
|
|
P2Y Receptor
|
Cancer
|
|
P2Y1/P2Y12 antagonist-1 (compound 24w) is an orally available dual inhibitor of P2Y1 and P2Y12 with antiplatelet activity. P2Y1/P2Y12 antagonist-1 inhibits ADP-induced platelet aggregation in rabbit plasma with an IC50 of 4.23 μM. P2Y1/P2Y12 antagonist-1 exhibits potent inhibitory effects in rat thrombosis model.
|
-
- HY-N2515R
-
|
|
NF-κB
PI3K
JAK
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
Ginsenoside Rk1 (Standard) is the analytical standard of Ginsenoside Rk1. This product is intended for research and analytical applications. Ginsenoside Rk1 is a unique component created by processing the ginseng plant (mainly Sung Ginseng, SG) at high temperatures .
Ginsenoside Rk1 has anti-inflammatory effect, suppresses the activation of Jak2/Stat3 signaling pathway and NF-κB .
Ginsenoside Rk1 has anti-tumor effect, antiplatelet aggregation activities, anti-insulin resistance, nephroprotective effect, antimicrobial effect, cognitive function enhancement, lipid accumulation reduction and prevents osteoporosis .
Ginsenoside Rk1 induces cell apoptosis by triggering intracellular reactive oxygen species (ROS) generation and blocking PI3K/Akt pathway .
|
-
- HY-P1956A
-
|
HSA (Cell culture grade, Endotoxin<0.125 EU/mg)
|
NF-κB
NO Synthase
|
Cardiovascular Disease
Inflammation/Immunology
|
|
Human serum albumin (Cell culture grade, Endotoxin<0.125 EU/mg) (HSA) is the most abundant protein in plasma and is a major determinant of plasma oncotic pressure. Human serum albumin (Cell culture grade, Endotoxin<0.125 EU/mg) exhibits antioxidant, anticoagulant, anti-inflammatory, anti-platelet aggregation activities as well as colloid osmotic action. Human serum albumin (Cell culture grade, Endotoxin<0.125 EU/mg) can block the inhibitory effect of GML on human T cells, providing protective function for T cells. Human serum albumin (Cell culture grade, Endotoxin<0.125 EU/mg) is also associated with cardiovascular diseases and can partially prevent the LPS (HY-D1056) induced oxidative stress, as well as the upregulation of NF-κB, iNOS, and peroxynitrite (ONOO −) in the vascular wall, contributing to the reduction of blood pressure .
|
-
| Cat. No. |
Product Name |
Type |
-
- HY-NP026
-
|
C-phycocyaninfromporphyratenera
|
Native Proteins
|
|
Spirulina C-phycocyanin, a component of the light-harvesting phycobilisome complex in photosystem II, is a highly dominant chromoprotein in Spirulina. Spirulina C-phycocyanin can be detected by Raman spectral measurement. Spirulina C-phycocyanin has antioxidant, anti-inflammatory, antiplatelet, liver-protective and cholesterol-lowering effects .
|
-
- HY-P1956
-
|
HSA
|
Native Proteins
|
|
Human serum albumin (HSA) is the most abundant protein in plasma and is a major determinant of plasma oncotic pressure. Human serum albumin exhibits antioxidant, anticoagulant, anti-inflammatory, anti-platelet aggregation activities as well as colloid osmotic action. Human serum albumin can block the inhibitory effect of GML on human T cells, providing protective function for T cells. Human serum albumin is also associated with cardiovascular diseases and can partially prevent the LPS (HY-D1056) induced oxidative stress, as well as the upregulation of NF-κB, NF-κB, and peroxynitrite (ONOO −) in the vascular wall, contributing to the reduction of blood pressure .
|
-
- HY-P1956A
-
|
HSA (Cell culture grade, Endotoxin<0.125 EU/mg)
|
Native Proteins
|
|
Human serum albumin (Cell culture grade, Endotoxin<0.125 EU/mg) (HSA) is the most abundant protein in plasma and is a major determinant of plasma oncotic pressure. Human serum albumin (Cell culture grade, Endotoxin<0.125 EU/mg) exhibits antioxidant, anticoagulant, anti-inflammatory, anti-platelet aggregation activities as well as colloid osmotic action. Human serum albumin (Cell culture grade, Endotoxin<0.125 EU/mg) can block the inhibitory effect of GML on human T cells, providing protective function for T cells. Human serum albumin (Cell culture grade, Endotoxin<0.125 EU/mg) is also associated with cardiovascular diseases and can partially prevent the LPS (HY-D1056) induced oxidative stress, as well as the upregulation of NF-κB, iNOS, and peroxynitrite (ONOO −) in the vascular wall, contributing to the reduction of blood pressure .
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-107146
-
|
P1pal-7
|
Protease Activated Receptor (PAR)
|
Cardiovascular Disease
Cancer
|
|
PZ-128 (P1pal-7), a cell-penetrating lipopeptide pepducin, is a first-in-class, specific and reversible protease-activated receptor-1 (PAR1) antagonist. PZ-128 targets the cytoplasmic surface of PAR1 and interrupts signaling to internally-located G (PAR1-G) proteins. PZ-128 has antiplatelet, anti-metastatic, anti-angiogenic and anticancer effects .
|
-
- HY-B0686B
-
|
|
Integrin
|
Cardiovascular Disease
|
|
Eptifibatide acetate is a cyclic heptapeptide, acts as a competitive antagonist for the activated platelet glycoprotein IIb/IIIa receptor, with anti-platelet activity .
|
-
- HY-B0686
-
Eptifibatide
Maximum Cited Publications
6 Publications Verification
|
Integrin
|
Cardiovascular Disease
|
|
Eptifibatide is a cyclic heptapeptide, acts as a competitive antagonist for the activated platelet glycoprotein IIb/IIIa receptor, with anti-platelet activity .
|
-
- HY-B0686A
-
|
|
Integrin
|
Cardiovascular Disease
|
|
Eptifibatide monoacetate is a cyclic heptapeptide, acts as a competitive antagonist for the activated platelet glycoprotein IIb/IIIa receptor, with anti-platelet activity .
|
-
- HY-B0686BR
-
|
|
Integrin
|
Cardiovascular Disease
|
|
Eptifibatide (acetate) (Standard) is the analytical standard of Eptifibatide (acetate). This product is intended for research and analytical applications. Eptifibatide acetate is a cyclic heptapeptide, acts as a competitive antagonist for the activated platelet glycoprotein IIb/IIIa receptor, with anti-platelet activity .
|
-
- HY-P3082
-
|
|
Peptides
|
Cardiovascular Disease
|
|
SKF 106760 is a potent platelet fibrin receptor (glycoprotein IIb/IIIa) antagonist with significant antiplatelet and antithrombotic activities. SKF 106760 inhibits platelet aggregation in dogs in vitro and prevents thrombus formation in stenotic carotid arteries. SKF 106760 has also shown elimination effects against aspirin-resistant thrombi that develop in the setting of high-grade stenosis .
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P99469
-
|
PB 2452; MEDI 2452
|
Inhibitory Antibodies
|
Metabolic Disease
|
|
Bentracimab (PB 2452) is a neutralizing monoclonal antibody that binds Ticagrelor (HY-1006) and its major active circulating metabolite with high affinity. Bentracimab can rapidly reverse the antiplatelet effect of Ticagrelor .
|
-
- HY-P99560
-
|
C4G1; YM-337
|
Integrin
|
Cardiovascular Disease
|
|
Tadocizumab (C4G1; YM-337) is a humanized monoclonal antibody tageting integrin αIIbβ3. Tadocizumab has antiplatelet and antithrombotic effects, and can be used for cardiovascular disease research .
|
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
-
- HY-N2299
-
-
-
- HY-N2909
-
-
-
- HY-N2081
-
-
-
- HY-N6020A
-
-
-
- HY-N7991
-
-
-
- HY-N1861
-
-
-
- HY-N3048
-
-
-
- HY-125123
-
-
-
- HY-N15271
-
-
-
- HY-N2081R
-
-
-
- HY-N11920
-
-
-
- HY-N9488
-
-
-
- HY-N0293
-
-
-
- HY-N3729
-
-
-
- HY-N1723
-
-
-
- HY-N0293R
-
|
|
Structural Classification
Other Monoterpenes
Paeonia lactiflora Pall.
Terpenoids
Source classification
Plants
Paeoniaceae
|
HSP
|
|
Paeoniflorin (Standard) is the analytical standard of Paeoniflorin. This product is intended for research and analytical applications. Paeoniflorin is a heat shock protein-inducing compound and commonly exists in the plants of Paeoniaceae family, with various biological activities, including anticancer activity, anti-inflammatory activity, enhancing cognition and attenuating learning impairment, anti-oxidative stress, antiplatelet aggregation, expansion of blood vessels, and reducing blood viscosity .
|
-
-
- HY-N3051
-
-
-
- HY-33351
-
-
-
- HY-125323
-
-
-
- HY-N0320
-
-
-
- HY-N3047
-
-
-
- HY-N1505
-
-
-
- HY-N3668
-
-
-
- HY-N3049
-
-
-
- HY-N6020
-
-
-
- HY-N1505R
-
-
-
- HY-N12647
-
-
-
- HY-N6806
-
-
-
- HY-169788
-
-
-
- HY-N0320R
-
-
-
- HY-126562
-
-
-
- HY-N8425
-
-
-
- HY-N12067
-
-
-
- HY-N0607
-
-
-
- HY-N6020B
-
-
-
- HY-N3665
-
-
-
- HY-N6005
-
-
-
- HY-N8425R
-
-
-
- HY-134650
-
-
-
- HY-N0120
-
-
-
- HY-N0607R
-
-
-
- HY-N3646
-
-
-
- HY-N2375
-
-
-
- HY-W017158R
-
-
-
- HY-124371
-
|
|
Structural Classification
Flavonoids
Viburnaceae
Source classification
Plants
Biflavones
Viburnum lantana L.
|
Phosphodiesterase (PDE)
|
|
Amentoflavone hexaacetate is a 3,5-cyclic nucleotide phosphodiesterase inhibitor with antiplatelet aggregation activity. Amentoflavone hexaacetate can inhibit the aggregation of eluted human platelets induced by ADP or collagen. Amentoflavone hexaacetate can also inhibit the cAMP phosphodiesterase activity in human platelets. Amentoflavone hexaacetate can significantly increase the cAMP level of platelets in the presence of prostaglandin E1. Amentoflavone hexaacetate has anti-angiogenic and anti-metastatic effects .
|
-
-
- HY-W012814
-
-
-
- HY-N2435
-
-
-
- HY-N2515
-
-
-
- HY-N2435R
-
|
|
Zingiber officinale Roscoe
Structural Classification
Monophenols
Source classification
Phenols
Plants
Zingiberaceae
|
COX
Apoptosis
|
|
-Shogaol (Standard) is the analytical standard of -Shogaol. This product is intended for research and analytical applications. -Shogaol, a kind of stimulating compound in ginger, has antiplatelet (IC50=5 μM), anti-cancer and anti-inflammatory activity. -Shogaol inhibited COX-2 (IC50=17.5 μM), which led to the decline of human leukemia cells. 8-Shogaol Selective direction TAK1 sum TAK1-TAB1 (IC50=5 μM), suppress IKK, Akt sum MAPK signal pathway, and reverse synovitis synovial sum Air dampness (RA) .
|
-
-
- HY-113469R
-
|
|
Structural Classification
Natural Products
Human Gut Microbiota Metabolites
Microorganisms
Source classification
Endogenous metabolite
|
STING
Endogenous Metabolite
|
|
Cyclic GMP (Standard) is the analytical standard of Cyclic GMP. This product is intended for research and analytical applications. Cyclic GMP is an endogenous second messenger that triggers interferon production in response to cytoplasmic DNA. Cyclic GMP can activate the stimulator of interferon genes (STING), activating the signaling cascade that leads to the production of type I interferons and other immune mediators. Cyclic-GMP-AMP, a conjugate of cyclic GMP and AMP, can induce IRF3 phosphorylation and nuclear translocation, enhancing antiviral immune responses. Cyclic GMP may also activate PDE to degrade cAMP, inhibit myocardial calcium current ICa, and regulate myocardial contractility. The derivative of Cyclic GMP, 8-Br-cGMP, has antiplatelet activity, and Cyclic GMP can be used in the study of antiviral immunity and cardiovascular diseases.
|
-
- HY-113469A
-
|
|
Structural Classification
Natural Products
Classification of Application Fields
Source classification
Endogenous metabolite
Inflammation/Immunology
Disease Research Fields
|
STING
Endogenous Metabolite
|
|
Cyclic GMP (cGAMP) sodium is an endogenous second messenger that triggers interferon production in response to cytoplasmic DNA. Cyclic GMP sodium can activate the stimulator of interferon genes (STING), activating the signaling cascade that leads to the production of type I interferons and other immune mediators. Cyclic-GMP-AMP, a conjugate of cyclic GMP and AMP, can induce IRF3 phosphorylation and nuclear translocation, enhancing antiviral immune responses. Cyclic GMP sodium may also activate PDE to degrade cAMP, inhibit myocardial calcium current ICa, and regulate myocardial contractility. The derivative of Cyclic GMP sodium, 8-Br-cGMP, has antiplatelet activity, and Cyclic GMP sodium can be used in the study of antiviral immunity and cardiovascular diseases .
|
-
- HY-113469
-
|
|
Structural Classification
Natural Products
Human Gut Microbiota Metabolites
Microorganisms
Source classification
Endogenous metabolite
|
STING
Endogenous Metabolite
|
|
Cyclic GMP (cGAMP) is an endogenous second messenger that triggers interferon production in response to cytoplasmic DNA. Cyclic GMP can activate the stimulator of interferon genes (STING), activating the signaling cascade that leads to the production of type I interferons and other immune mediators. Cyclic-GMP-AMP, a conjugate of cyclic GMP and AMP, can induce IRF3 phosphorylation and nuclear translocation, enhancing antiviral immune responses. cGMP may also activate PDE to degrade cAMP, inhibit myocardial calcium current ICa, and regulate myocardial contractility. The derivative of cyclic GMP (cGMP), 8-Br-cGMP, has antiplatelet activity, and cyclic GMP can be used in the study of antiviral immunity and cardiovascular diseases .
|
-
- HY-N2515R
-
|
|
Panax ginseng C. A. Meyer
Triterpenes
Structural Classification
Terpenoids
Source classification
Plants
Araliaceae
|
NF-κB
PI3K
JAK
Apoptosis
|
|
Ginsenoside Rk1 (Standard) is the analytical standard of Ginsenoside Rk1. This product is intended for research and analytical applications. Ginsenoside Rk1 is a unique component created by processing the ginseng plant (mainly Sung Ginseng, SG) at high temperatures .
Ginsenoside Rk1 has anti-inflammatory effect, suppresses the activation of Jak2/Stat3 signaling pathway and NF-κB .
Ginsenoside Rk1 has anti-tumor effect, antiplatelet aggregation activities, anti-insulin resistance, nephroprotective effect, antimicrobial effect, cognitive function enhancement, lipid accumulation reduction and prevents osteoporosis .
Ginsenoside Rk1 induces cell apoptosis by triggering intracellular reactive oxygen species (ROS) generation and blocking PI3K/Akt pathway .
|
-
| Cat. No. |
Product Name |
Chemical Structure |
-
- HY-W777681
-
|
|
|
Triflusal-13C6 is a C13-labeled Triflusal. Triflusal is a platelet aggregation inhibitor .
|
-
-
- HY-141749AS
-
|
|
|
Clopidogrel carboxylic acid-d4 is a deuterated derivative of Clopidogrel carboxylic acid, which is an inactive metabolite of the antiplatelet agent Clopidogrel (HY-15283) in plasma. Clopidogrel carboxylic acid-d4 can be used to further explore the metabolic characteristics of Clopidogrel .
|
-
-
- HY-10119S
-
|
|
|
Vorapaxar-d5 is deuterated labeled Vorapaxar (HY-10119). Vorapaxar (SCH 530348), an antiplatelet agent, is a selective, orally active, and competitive thrombin receptor protease-activated receptor (PAR-1) antagonist (Ki=8.1 nM). Vorapaxar (SCH 530348) inhibits thrombin receptor-activating peptide (TRAP)-induced platelet aggregation in a dose-dependent manner .
|
-
-
- HY-17459S
-
|
|
|
Clopidogrel-d3 (hydrogen sulfate) is the deuterium labeled Clopidogrel hydrogen sulfate[1]. Clopidogrel hydrogen sulfate is an antiplatelet agent to prevent blood clots. Clopidogrel hydrogen sulfate inhibits CYP2B6 and CYP2C19 with IC50s of 18.2 nM and 524 nM, respectively. Clopidogrel hydrogen sulfate is a potent antithrombotic agent that inhibits ADP-induced platelet aggregation．Clopidogrel hydrogen sulfate also is an orally active P2Y(12) inhibitor[2][3][4][5][6].
|
-
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent:
![[8]-Shogaol](http://file.medchemexpress.eu/product_pic/hy-n2435.gif)
![[8]-Shogaol (Standard)](http://file.medchemexpress.eu/product_pic/hy-n2435r.gif)
